# A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

> **NCT00503113** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 801 (actual)

## Conditions studied

- Post-Menopausal Osteoporosis

## Interventions

- **DRUG:** ibandronate [Bonviva/Boniva]
- **DRUG:** ibandronate [Bonviva/Boniva]
- **DRUG:** Alendronate

## Key facts

- **NCT ID:** NCT00503113
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 801 (ACTUAL)
- **Last updated:** 2011-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00503113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00503113, "A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00503113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*